Sector News

China to scrap drug price caps next year -state newspaper

November 26, 2014
Life sciences
(Reuters) – China plans to scrap retail price caps on all drugs as early as the start of next year, an official newspaper reported on Wednesday, giving the market a larger role in an industry where price controls have contributed to supply shortages.
 
The National Development and Reform Commission, China’s planning agency, has prepared a draft law for review by the industry and could lift the caps as early as Jan. 1, the official Securities Times reported on its website.
 
Officials at the NDRC had no immediate comment on the report.
 
China has been slowly stepping back from caps on consumer prices for drugs but faces a difficult task balancing the need to ensure steady supplies of vital medicines with its desire to keep prices low.
 
China removed price caps on a limited number of drugs in April after criticism that its controls had caused shortages of a number of critical drugs used by millions of patients to treat hyperthyroidism and other ailments.
 
The full removal of caps should ease price pressures on both domestic and international pharmaceutical firms hoping to tap a healthcare market that McKinsey & Co estimates will grow to $1 trillion by 2020, nearly triple its size in 2011.
 
A recent crackdown on high prices pushed some Chinese firms out of business and forced global drugmakers – which have long banked on being able to charge steep premiums in emerging markets – to rethink their China strategy.
 
The caps, however, play only a limited role in the government’s price control regime, analysts said, with around two-thirds of drugs still sold in China’s vast hospital network where prices are kept low through a tendering system.
 
“We continue to expect very limited impact, since most drugs are sold in hospitals and the pricing is determined by tender process,” Deutsche Bank healthcare analyst Jack Hu said in a note on Wednesday.
 
President Xi Jinping has made a priority of providing affordable, accessible healthcare in a country struggling with rising healthcare costs, long waits for care and lapses in medicine safety.
 
The draft rules, which were sent to eight industry bodies on Tuesday seeking feedback, propose to “cancel government-set prices on drugs, and through insurance price controls and the tendering process, allow the actual transaction price of drugs to be set by market competition,” the newspaper said.
 
Prices would be set by a combination of health insurance departments, existing tendering processes and multi-stakeholder negotiations, it said. (Reporting by Adam Jourdan; Additional reporting by Shanghai Newsroom; Editing by Edmund Klamann)

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach